Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 7,390 matching trials from the live ClinicalTrials.gov search.
Conditions
Healthy
Interventions
Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cypress, California
Conditions
Normal Renal Function, Impaired Renal Function
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
JNJ-64264681
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Terminated Phase 2 Interventional Results available

A Study of Ponsegromab in People With Heart Failure

NCT05492500
Conditions
Heart Failure
Interventions
Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Main cohort (Cohort A): Matched placebo, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort C: Matched placebo, Optional Cohort D: Ponsegromab high dose, Optional Cohort D: Matched placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
Conditions
Graft-versus-host Disease
Interventions
Neihulizumab, 3 mg/kg, Neihulizumab, 6 mg/kg, Neihulizumab, 9 mg/kg, Neihulizumab
Biological · Drug
Lead sponsor
Sameem M. Abedin, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Microbiota, Oral Health, Body Mass Index
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hepatocellular Carcinoma, Biliary Tract Cancer
Interventions
RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
12
States / cities
Beverly Hills, California • La Jolla, California • Miami, Florida + 9 more
Conditions
Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 17 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Life Length SL
Industry
Eligibility
18 Years and older · Male only
Enrollment
509 participants
Timeline
2019 – 2023
U.S. locations
2
States / cities
Hialeah, Florida • Houston, Texas
Conditions
Solid Tumors
Interventions
Genz-644282 (28-day dosing schedule), Genz-644282 (21-day dosing schedule)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 1 more
Conditions
Multiple Myeloma
Interventions
VELCADE™
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Years to 17 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more
Conditions
Glioblastoma
Interventions
Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a
Drug
Lead sponsor
SignPath Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

NCT03580928
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
Venetoclax, Obinutuzumab, Acalabrutinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Stamford, Connecticut • Boston, Massachusetts • Providence, Rhode Island
Conditions
Weight Loss, Pediatric Obesity
Interventions
iAmHealthy Parents First, iAmHealthy
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
6 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Non-small Cell Lung Cancer, NSCLC
Interventions
AMG 160
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, CD20 Positive, Diffuse Large B-Cell Lymphoma Unclassifiable, Intravascular Large B-Cell Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab, Prednisone, Quality-of-Life Assessment, Rituximab, Vincristine Sulfate
Drug · Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois
Conditions
Healthy
Interventions
Mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Music Training and Child Development Study

NCT05502939
Conditions
Music
Interventions
Music Program, After School Enrichment Program
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
6 Years to 8 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3)
Interventions
Codrituzumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 2 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)

NCT04788277
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection
Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
50 Years to 79 Years · Male only
Enrollment
810 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Patient-centered Care
Interventions
REACH - Hypertension
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
High Grade Squamous Intraepithelial Neoplasia, Stage 0 Uterine Corpus Cancer
Interventions
Biopsy, Laboratory Biomarker Analysis, Megestrol Acetate, Pharmacological Study, Quality-of-Life Assessment, Therapeutic Conventional Surgery
Procedure · Other · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
50
States / cities
Los Angeles, California • Sylmar, California • Hartford, Connecticut + 34 more
Conditions
Type 2 Diabetes Mellitus
Interventions
SAR425899
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee • Austin, Texas